期刊
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
卷 20, 期 2, 页码 195-207出版社
SPRINGER
DOI: 10.1007/s00775-014-1210-x
关键词
Xanthine oxidase; Uric acid; Allopurinol; Febuxostat; Gout
资金
- Grants-in-Aid for Scientific Research [26440081, 24590393] Funding Source: KAKEN
Xanthine oxidoreductase (XOR), which is widely distributed from humans to bacteria, has a key role in purine catabolism, catalyzing two steps of sequential hydroxylation from hypoxanthine to xanthine and from xanthine to urate at its molybdenum cofactor (Moco). Human XOR is considered to be a target of drugs not only for therapy of hyperuricemia and gout, but also potentially for a wide variety of other diseases. In this review, we focus on studies of XOR inhibitors and their implications for understanding the chemical nature and reaction mechanism of the Moco active site of XOR. We also discuss further experimental or clinical studies that would be helpful to clarify remaining issues.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据